STOCK TITAN

Bicycle Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Bicycle Therapeutics plc (NASDAQ: BCYC) will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 1:10 p.m. ET. The chat will be available via a live webcast on Bicycle's website, with an archived replay accessible for 90 days post-event. Bicycle Therapeutics is advancing a new class of therapeutics called Bicycles that target underserved diseases. Their lead candidate, BT1718, is undergoing trials focusing on cancer treatment.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, England & BOSTON--()--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 1:10 p.m. ET.

A live webcast of the fireside chat will be accessible in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the presentation date.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

Contacts

Investor and Media Contact:
Bicycle Therapeutics
Maren Killackey
maren.killackey@bicycletx.com
+1-617-203-8300

FAQ

When is Bicycle Therapeutics participating in the Jefferies Virtual London Healthcare Conference?

Bicycle Therapeutics will participate in the conference on November 19, 2020, at 1:10 p.m. ET.

How can I access the webcast of Bicycle Therapeutics' fireside chat?

The webcast will be accessible on Bicycle's website during and after the event.

What is Bicycle Therapeutics' lead product candidate?

Bicycle Therapeutics' lead candidate is BT1718, a Bicycle Toxin Conjugate targeting MT1-MMP.

What is the focus of Bicycle Therapeutics' drug development?

Bicycle Therapeutics focuses on developing therapies for diseases that lack effective treatments.

How long will the archived replay of the webcast be available?

The archived replay of the webcast will be available for 90 days following the presentation.

Bicycle Therapeutics plc American Depositary Shares

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Stock Data

1.04B
46.59M
1.3%
92.36%
5.1%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE